Exozymes (EXOZ) Long-Term Deferred Tax (2025 - 2026)
Exozymes (EXOZ) posted quarterly Long-Term Deferred Tax of $105205.0 for Q4 2025.
Exozymes (EXOZ) Long-Term Deferred Tax (2025 - 2026) Analysis & Trends
Exozymes (EXOZ) has reported Long-Term Deferred Tax for 1 consecutive years, with $105205.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Long-Term Deferred Tax changed N/A year-over-year to $105205.0; the TTM figure through Dec 2025 stood at $105205.0 (changed N/A YoY), while the FY2025 annual figure was $105205.0, changed N/A from the prior year.
- Long-Term Deferred Tax was little changed at $105205.0 in Q4 2025 per EXOZ's latest filing.
- Across five years, Long-Term Deferred Tax topped out at $105205.0 in Q4 2025 and bottomed at $105205.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Exozymes | 62.35 Mn | 62.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 105,205.00 |
| Dec 31, 2025 | 105,205.00 |